These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9173721)

  • 1. [Effects of lipid lowering measures on coronary perfusion].
    Steinmetz A; Maisch B; Noll B
    Z Kardiol; 1997; 86 Suppl 1():43-55. PubMed ID: 9173721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Modifying increased plasma cholesterol levels in secondary prevention of coronary heart disease].
    Jost S; Lichtlen PR
    Z Kardiol; 1995 Aug; 84(8):577-95. PubMed ID: 7571764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease.
    van der Harst P; Wagenaar LJ; Buikema H; Voors AA; Plokker HW; Morshuis WJ; Six AJ; Boonstra PW; Nickenig G; Wassmann S; van Veldhuisen DJ; van Gilst WH
    Am J Cardiol; 2005 Nov; 96(10):1361-4. PubMed ID: 16275178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid lowering and coronary risk.
    Gotto AM
    Isr J Med Sci; 1996 Jun; 32(6):355-9. PubMed ID: 8682640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of hyperlipidemia].
    Keller C
    Wien Med Wochenschr; 1994; 144(12-13):330-2. PubMed ID: 8650939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherosclerotic lesions in humans--plaque stabilization and regression.
    Kritz H; Sinzinger H
    Wien Klin Wochenschr; 1995; 107(18):555-66. PubMed ID: 7483643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of reduced cholesterol on coronary arteries].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 1998 Oct; 118(24):3805-9. PubMed ID: 9816952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lipid lowering therapy: new pathophysiologic aspects and clinical implications].
    Nordmann A; Martina B; Keller U; Battegay E
    Schweiz Med Wochenschr; 1998 Apr; 128(17):665-70. PubMed ID: 9622839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of antilipidemic therapies in chronic renal allograft failure.
    Wanner C; Bartens W; Galle J
    Kidney Int Suppl; 1995 Dec; 52():S60-2. PubMed ID: 8587286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Goals and practical implementation of lipid therapy in coronary heart disease].
    Beil FU; Windler E
    Herz; 1997 Jun; 22(3):134-40. PubMed ID: 9303897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In patients with coronary artery disease endothelial function is associated with plasma levels of C-reactive protein and is improved by optimal medical therapy.
    Vitale C; Cerquetani E; Wajngarten M; Leonardo F; Silvestri A; Mercuro G; Fini M; Ramires JA; Rosano GM
    Ital Heart J; 2003 Sep; 4(9):627-32. PubMed ID: 14635381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversing coronary atherosclerosis. How to put findings of recent trials to practical use.
    Kahn JK
    Postgrad Med; 1993 Jul; 94(1):50-2, 55-7, 60-5. PubMed ID: 8321785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of lipid metabolism disorders in the elderly].
    Mizera W; Grzeszczak W
    Wiad Lek; 1998; 51 Suppl 2():52-7. PubMed ID: 9686534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis.
    Ganz P; Creager MA; Fang JC; McConnell MV; Lee RT; Libby P; Selwyn AP
    Am J Med; 1996 Oct; 101(4A):4A10S-16S. PubMed ID: 8900332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of hyperlipidemia in patients with ischemic heart disease].
    Pauciullo P; Lirato C; Sapio C; Mancini M
    Cardiologia; 1993 Dec; 38(12 Suppl 1):345-8. PubMed ID: 8020035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy].
    Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III6-27. PubMed ID: 14663597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of l-arginine in a porcine model of endothelial dysfunction.
    Voisine P; Bianchi C; Khan TA; Ruel M; Xu SH; Feng J; Li J; Malik T; Rosinberg A; Sellke FW
    J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1414-20. PubMed ID: 15942586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.